Clinical Trial Update: Docetaxel and Bortezomib in Treating Patients With Progressive or Recurrent Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 study evaluating docetaxel plus bortezomib in patients with progressive or recurrent non-small cell lung cancer has completed and results have been post…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Bortezomib (bortezomib)
• DOCETAXEL (DOCETAXEL)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Non-small Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer | Phase 2 | Status: COMPLETED | Results posted: 2014-10-02